Clinuvel Pharmaceuticals (CUVL) vs Turn Therapeutics (TTRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Turn Therapeutics (TTRX) has outperformed Clinuvel Pharmaceuticals (CUVL) over the past year, gaining 30.4% versus a loss of 30.6%. Turn Therapeutics is the larger company by market cap ($364.4 million vs $282.2 million), about 1.3 times the size. Clinuvel Pharmaceuticals pays a dividend yielding 0.89%, while Turn Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUVL | TTRX |
|---|---|---|
| Share price | $5.59 | $12.00 |
| Market cap | $282.22M | $364.41M |
| 1-day change | -0.18% | +5.36% |
| YTD return | -34.08% | +204.57% |
| 1-year return | -30.65% | +30.43% |
| 5-year return | -81.64% | — |
| P/E ratio (TTM) | 12.42 | — |
| EPS (TTM) | $0.45 | $-0.29 |
| Dividend yield | 0.89% | 0.00% |
| Annual dividend | $0.05 | $0.00 |
| 52-week high | $8.92 | $16.45 |
| 52-week low | $5.53 | $2.57 |
| Distance from 52-week high | -37.33% | -27.05% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +108.33% |
| Average volume | 13.02K | 109.59K |
| Shares outstanding | 50.49M | 30.37M |
| Employees | — | 2 |
| Sector | Miscellaneous | Health Care |
| Industry | Miscellaneous | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TTRX has outperformed CUVL by 61.1 percentage points over the past year.
- The two companies sit in different sectors: Clinuvel Pharmaceuticals in Miscellaneous and Turn Therapeutics in Health Care.
About Clinuvel Pharmaceuticals
CUVL stock →Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Miscellaneous · Miscellaneous
About Turn Therapeutics
TTRX stock →Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
CUVL vs TTRX FAQ
Which is bigger, Clinuvel Pharmaceuticals or Turn Therapeutics?
Turn Therapeutics (TTRX) is larger, with a market capitalization of $364.41M compared with $282.22M for Clinuvel Pharmaceuticals (CUVL).
Which stock has performed better over the past year, CUVL or TTRX?
TTRX returned +30.43% over the past 12 months, compared with -30.65% for CUVL (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Clinuvel Pharmaceuticals or Turn Therapeutics?
Clinuvel Pharmaceuticals pays a dividend yielding 0.89%, while Turn Therapeutics does not currently pay a regular dividend.
Are Clinuvel Pharmaceuticals and Turn Therapeutics in the same industry?
No. Clinuvel Pharmaceuticals is in the Miscellaneous sector, while Turn Therapeutics is in Health Care.